Skip to main content

HCPCS Level II

HCPCS Level II 2013 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2013, grouped by effective date. Each code's own page carries its full record.

162
Added
0
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2013 (150)

  • A4435 — Ostomy pouch, drainable, high output, with extended wear barrier (one-piece system), with or without filter, each
  • A9586 — Florbetapir f18, diagnostic, per study dose, up to 10 millicuries
  • C9600 — Percutaneous transcatheter placement of drug eluting intracoronary stent(s), with coronary angioplasty when performed; single major coronary artery or branch
  • C9601 — Percutaneous transcatheter placement of drug-eluting intracoronary stent(s), with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
  • C9602 — Percutaneous transluminal coronary atherectomy, with drug eluting intracoronary stent, with coronary angioplasty when performed; single major coronary artery or branch
  • C9603 — Percutaneous transluminal coronary atherectomy, with drug-eluting intracoronary stent, with coronary angioplasty when performed; each additional branch of a major coronary artery (list separately in addition to code for primary procedure)
  • C9604 — Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; single vessel
  • C9605 — Percutaneous transluminal revascularization of or through coronary artery bypass graft (internal mammary, free arterial, venous), any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including distal protection when performed; each additional branch subtended by the bypass graft (list separately in addition to code for primary procedure)
  • C9606 — Percutaneous transluminal revascularization of acute total/subtotal occlusion during acute myocardial infarction, coronary artery or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty, including aspiration thrombectomy when performed, single vessel
  • C9607 — Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; single vessel
  • C9608 — Percutaneous transluminal revascularization of chronic total occlusion, coronary artery, coronary artery branch, or coronary artery bypass graft, any combination of drug-eluting intracoronary stent, atherectomy and angioplasty; each additional coronary artery, coronary artery branch, or bypass graft (list separately in addition to code for primary procedure)
  • E0670 — Segmental pneumatic appliance for use with pneumatic compressor, integrated, 2 full legs and trunk
  • E2378 — Power wheelchair component, actuator, replacement only
  • G0452 — Molecular pathology procedure; physician interpretation and report
  • G0453 — Continuous intraoperative neurophysiology monitoring, from outside the operating room (remote or nearby), per patient, (attention directed exclusively to one patient) each 15 minutes (list in addition to primary procedure)
  • G0454 — Physician documentation of face-to-face visit for durable medical equipment determination performed by nurse practitioner, physician assistant or clinical nurse specialist
  • G0455 — Preparation with instillation of fecal microbiota by any method, including assessment of donor specimen
  • G0456 — Negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area less than or equal to 50 square centimeters
  • G0457 — Negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area greater than 50 square centimeters
  • G0458 — Low dose rate (ldr) prostate brachytherapy services, composite rate
  • G8923 — Current or prior left ventricular ejection fraction (lvef) <= 40% or documentation of moderately or severely depressed left ventricular systolic function
  • G8924 — Spirometry results documented (fev1/fvc < 70%)
  • G8925 — Spirometry test results demonstrate fev1 >= 60% fev1/fvc >= 70%, predicted or patient does not have copd symptoms
  • G8926 — Spirometry test not performed or documented, reason not given
  • G8927 — Adjuvant chemotherapy referred, prescribed or previously received for ajcc stage iii, colon cancer
  • G8928 — Adjuvant chemotherapy not prescribed or previously received, for documented reasons (e.g., medical co-morbidities, diagnosis date more than 5 years prior to the current visit date, patient's diagnosis date is within 120 days of the end of the 12 month reporting period, patient's cancer has metastasized, medical contraindication/allergy, poor performance status, other medical reasons, patient refusal, other patient reasons, patient is currently enrolled in a clinical trial that precludes prescription of chemotherapy, other system reasons)
  • G8929 — Adjuvant chemotherapy not prescribed or previously received, reason not given
  • G8930 — Assessment of depression severity at the initial evaluation
  • G8931 — Assessment of depression severity not documented, reason not given
  • G8932 — Suicide risk assessed at the initial evaluation
  • G8933 — Suicide risk not assessed at the initial evaluation, reason not given
  • G8934 — Current or prior left ventricular ejection fraction (lvef) <=40% or documentation of moderately or severely depressed left ventricular systolic function
  • G8935 — Clinician prescribed angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy
  • G8936 — Clinician documented that patient was not an eligible candidate for angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy (eg, allergy, intolerance, pregnancy, renal failure due to ace inhibitor, diseases of the aortic or mitral valve, other medical reasons) or (eg, patient declined, other patient reasons)
  • G8937 — Clinician did not prescribe angiotensin converting enzyme (ace) inhibitor or angiotensin receptor blocker (arb) therapy, reason not given
  • G8938 — Bmi is documented as being outside of normal parameters, follow-up plan is not documented, documentation the patient is not eligible
  • G8939 — Pain assessment documented as positive, follow-up plan not documented, documentation the patient is not eligible at the time of the encounter
  • G8940 — Screening for depression documented as positive, a follow-up plan not completed, documented reason
  • G8941 — Elder maltreatment screen documented as positive, follow-up plan not documented, documentation the patient is not eligible for follow-up plan at the time of the encounter
  • G8942 — Functional outcome assessment using a standardized tool is documented within the previous 30 days and a care plan, based on identified deficiencies is documented within two days of the functional outcome assessment
  • G8943 — Ldl-c result not present or not within 12 months prior
  • G8944 — Ajcc melanoma cancer stage 0 through iic melanoma
  • G8946 — Minimally invasive biopsy method attempted but not diagnostic of breast cancer (e.g., high risk lesion of breast such as atypical ductal hyperplasia, lobular neoplasia, atypical lobular hyperplasia, lobular carcinoma in situ, atypical columnar hyperplasia, flat epithelial atypia, radial scar, complex sclerosing lesion, papillary lesion, or any lesion with spindle cells)
  • G8947 — One or more neuropsychiatric symptoms
  • G8948 — No neuropsychiatric symptoms
  • G8949 — Documentation of patient reason(s) for patient not receiving counseling for diet and physical activity (e.g., patient is not willing to discuss diet or exercise interventions to help control blood pressure, or the patient said he/she refused to make these changes)
  • G8950 — Elevated or hypertensive blood pressure reading documented, and the indicated follow-up is documented
  • G8951 — Pre-hypertensive or hypertensive blood pressure reading documented, indicated follow-up not documented, documentation the patient is not eligible
  • G8952 — Elevated or hypertensive blood pressure reading documented, indicated follow-up not documented, reason not given
  • G8953 — All quality actions for the applicable measures in the oncology measures group have been performed for this patient
  • G8955 — Most recent assessment of adequacy of volume management documented
  • G8956 — Patient receiving maintenance hemodialysis in an outpatient dialysis facility
  • G8957 — Patient not receiving maintenance hemodialysis in an outpatient dialysis facility
  • G8958 — Assessment of adequacy of volume management not documented, reason not given
  • G8959 — Clinician treating major depressive disorder communicates to clinician treating comorbid condition
  • G8960 — Clinician treating major depressive disorder did not communicate to clinician treating comorbid condition, reason not given
  • G8961 — Cardiac stress imaging test primarily performed on low-risk surgery patient for preoperative evaluation within 30 days preceding this surgery
  • G8962 — Cardiac stress imaging test performed on patient for any reason including those who did not have low risk surgery or test that was performed more than 30 days preceding low risk surgery
  • G8963 — Cardiac stress imaging performed primarily for monitoring of asymptomatic patient who had pci within 2 years
  • G8964 — Cardiac stress imaging test performed primarily for any other reason than monitoring of asymptomatic patient who had pci within 2 years (e.g., symptomatic patient, patient greater than 2 years since pci, initial evaluation, etc)
  • G8965 — Cardiac stress imaging test primarily performed on low chd risk patient for initial detection and risk assessment
  • G8966 — Cardiac stress imaging test performed on symptomatic or higher than low chd risk patient or for any reason other than initial detection and risk assessment
  • G8967 — Fda approved oral anticoagulant is prescribed
  • G8968 — Documentation of medical reason(s) for not prescribing an fda-approved anticoagulant (e.g., present or planned atrial appendage occlusion or ligation or patient being currently enrolled in a clinical trial related to af/atrial flutter treatment)
  • G8969 — Documentation of patient reason(s) for not prescribing an oral anticoagulant that is fda approved for the prevention of thromboembolism (e.g., patient preference for not receiving anticoagulation)
  • G8970 — No risk factors or one moderate risk factor for thromboembolism
  • G8971 — Warfarin or another oral anticoagulant that is fda approved not prescribed, reason not given
  • G8972 — One or more high risk factors for thromboembolism or more than one moderate risk factor for thromboembolism
  • G8973 — Most recent hemoglobin (hgb) level < 10 g/dl
  • G8974 — Hemoglobin level measurement not documented, reason not given
  • G8975 — Documentation of medical reason(s) for patient having a hemoglobin level < 10 g/dl (e.g., patients who have non-renal etiologies of anemia [e.g., sickle cell anemia or other hemoglobinopathies, hypersplenism, primary bone marrow disease, anemia related to chemotherapy for diagnosis of malignancy, postoperative bleeding, active bloodstream or peritoneal infection], other medical reasons)
  • G8976 — Most recent hemoglobin (hgb) level >= 10 g/dl
  • G8977 — I intend to report the oncology measures group
  • G8978 — Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8979 — Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8980 — Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8981 — Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8982 — Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8983 — Changing & maintaining body position functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8984 — Carrying, moving & handling objects functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8985 — Carrying, moving and handling objects, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8986 — Carrying, moving & handling objects functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8987 — Self care functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8988 — Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8989 — Self care functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8990 — Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8991 — Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8992 — Other physical or occupational therapy primary functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8993 — Other physical or occupational therapy subsequent functional limitation, current status, at therapy episode outset and at reporting intervals
  • G8994 — Other physical or occupational therapy subsequent functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8995 — Other physical or occupational therapy subsequent functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8996 — Swallowing functional limitation, current status at therapy episode outset and at reporting intervals
  • G8997 — Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G8998 — Swallowing functional limitation, discharge status, at discharge from therapy or to end reporting
  • G8999 — Motor speech functional limitation, current status at therapy episode outset and at reporting intervals
  • G9157 — Transesophageal doppler measurement of cardiac output (including probe placement, image acquisition, and interpretation per course of treatment) for monitoring purposes
  • G9158 — Motor speech functional limitation, discharge status, at discharge from therapy or to end reporting
  • G9159 — Spoken language comprehension functional limitation, current status at therapy episode outset and at reporting intervals
  • G9160 — Spoken language comprehension functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9161 — Spoken language comprehension functional limitation, discharge status, at discharge from therapy or to end reporting
  • G9162 — Spoken language expression functional limitation, current status at therapy episode outset and at reporting intervals
  • G9163 — Spoken language expression functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9164 — Spoken language expression functional limitation, discharge status at discharge from therapy or to end reporting
  • G9165 — Attention functional limitation, current status at therapy episode outset and at reporting intervals
  • G9166 — Attention functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9167 — Attention functional limitation, discharge status at discharge from therapy or to end reporting
  • G9168 — Memory functional limitation, current status at therapy episode outset and at reporting intervals
  • G9169 — Memory functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9170 — Memory functional limitation, discharge status at discharge from therapy or to end reporting
  • G9171 — Voice functional limitation, current status at therapy episode outset and at reporting intervals
  • G9172 — Voice functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9173 — Voice functional limitation, discharge status at discharge from therapy or to end reporting
  • G9174 — Other speech language pathology functional limitation, current status at therapy episode outset and at reporting intervals
  • G9175 — Other speech language pathology functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • G9176 — Other speech language pathology functional limitation, discharge status at discharge from therapy or to end reporting
  • G9186 — Motor speech functional limitation, projected goal status at therapy episode outset, at reporting intervals, and at discharge or to end reporting
  • J0178 — Injection, aflibercept, 1 mg
  • J0485 — Injection, belatacept, 1 mg
  • J0716 — Injection, centruroides immune f(ab)2, up to 120 milligrams
  • J0890 — Injection, peginesatide, 0.1 mg (for esrd on dialysis)
  • J1050 — Injection, medroxyprogesterone acetate, 1 mg
  • J1741 — Injection, ibuprofen, 100 mg
  • J1744 — Injection, icatibant, 1 mg
  • J2212 — Injection, methylnaltrexone, 0.1 mg
  • J7178 — Injection, human fibrinogen concentrate, not otherwise specified, 1 mg
  • J7315 — Mitomycin, ophthalmic, 0.2 mg
  • J7527 — Everolimus, oral, 0.25 mg
  • J9019 — Injection, asparaginase (erwinaze), 1,000 iu
  • J9042 — Injection, brentuximab vedotin, 1 mg
  • L5859 — Addition to lower extremity prosthesis, endoskeletal knee-shin system, powered and programmable flexion/extension assist control, includes any type motor(s)
  • L7902 — Tension ring, for vacuum erection device, any type, replacement only, each
  • L8605 — Injectable bulking agent, dextranomer/hyaluronic acid copolymer implant, anal canal, 1 ml, includes shipping and necessary supplies
  • Q4131 — Epifix or epicord, per square centimeter
  • Q4132 — Grafix core and grafixpl core, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4133 — Grafix prime, grafixpl prime, stravix and stravixpl, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4134 — Hmatrix, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4135 — Mediskin, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4136 — Ez-derm, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q9969 — Tc-99m from non-highly enriched uranium source, full cost recovery add-on, per study dose
  • S9110 — Telemonitoring of patient in their home, including all necessary equipment; computer system, connections, and software; maintenance; patient education and support; per month
  • V5281 — Assistive listening device, personal fm/dm system, monaural, (1 receiver, transmitter, microphone), any type
  • V5282 — Assistive listening device, personal fm/dm system, binaural, (2 receivers, transmitter, microphone), any type
  • V5283 — Assistive listening device, personal fm/dm neck, loop induction receiver
  • V5284 — Assistive listening device, personal fm/dm, ear level receiver
  • V5285 — Assistive listening device, personal fm/dm, direct audio input receiver
  • V5286 — Assistive listening device, personal blue tooth fm/dm receiver
  • V5287 — Assistive listening device, personal fm/dm receiver, not otherwise specified
  • V5288 — Assistive listening device, personal fm/dm transmitter assistive listening device
  • V5289 — Assistive listening device, personal fm/dm adapter/boot coupling device for receiver, any type
  • V5290 — Assistive listening device, transmitter microphone, any type

Added effective April 1, 2013 (5)

  • C9734 — Focused ultrasound ablation/therapeutic intervention, other than uterine leiomyomata, with magnetic resonance (mr) guidance
  • C9735 — Anoscopy; with directed submucosal injection(s), any substance
  • Q0507 — Miscellaneous supply or accessory for use with an external ventricular assist device
  • Q0508 — Miscellaneous supply or accessory for use with an implanted ventricular assist device
  • Q0509 — Miscellaneous supply or accessory for use with any implanted ventricular assist device for which payment was not made under medicare part a

Added effective July 1, 2013 (4)

  • K0008 — Custom manual wheelchair/base
  • K0013 — Custom motorized/power wheelchair base
  • K0900 — Customized durable medical equipment, other than wheelchair
  • Q2050 — Injection, doxorubicin hydrochloride, liposomal, not otherwise specified, 10 mg

Added effective October 1, 2013 (3)

  • C1841 — Retinal prosthesis, includes all internal and external components
  • C9132 — Prothrombin complex concentrate (human), kcentra, per i.u. of factor ix activity
  • G9187 — Bundled payments for care improvement initiative home visit for patient assessment performed by a qualified health care professional for individuals not considered homebound including, but not limited to, assessment of safety, falls, clinical status, fluid status, medication reconciliation/management, patient compliance with orders/plan of care, performance of activities of daily living, appropriateness of care setting; (for use only in the meidcare-approved bundled payments for care improvement initiative); may not be billed for a 30-day period covered by a transitional care management code

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2013
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger